Celularity And Verséa Ophthalmics Announce Exclusive U.S. Commercialization Agreement To Distribute Biovance And Biovance 3l Ocular For Ophthalmic Applications; Terms Of The Agreement Are Not Disclosed.
Portfolio Pulse from Happy Mohamed
Celularity Inc. (NASDAQ:CELU) and Verséa Ophthalmics have announced an exclusive U.S. commercialization agreement. Verséa Ophthalmics will distribute Celularity's BIOVANCE and BIOVANCE 3L Ocular products, which are intended for the treatment of ocular surface disease and ocular surgical applications. The global persistent corneal epithelial defect management market, which these products target, is valued at $8.5 billion and expected to grow at an 18% CAGR through 2033.
July 27, 2023 | 1:13 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Celularity's partnership with Verséa Ophthalmics for the distribution of its BIOVANCE products could potentially increase its market reach and revenues, given the high value and expected growth of the targeted market.
The partnership with Verséa Ophthalmics allows Celularity to tap into a market that is currently valued at $8.5 billion and is expected to grow significantly in the coming years. This could lead to increased sales and revenues for Celularity, positively impacting its stock price.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100